Your browser doesn't support javascript.
Potential interactions between antineoplastic agents and medicines used to treat Covid-19.
Sobreira da Silva, Mario Jorge; Serpa Osorio-de-Castro, Claudia Garcia; Paes, Rafael Duarte; Negrete, Christopher Lucas; Eugênio, Elizangela; Moraes, Elaine Lazzaroni; Livinalli, Annemeri.
  • Sobreira da Silva MJ; 37908National Cancer Institute of Brazil, Brazil.
  • Serpa Osorio-de-Castro CG; 42499Sergio Arouca National School of Public Health, Brazil.
  • Paes RD; 434749Oncoclinicas of Brazil, Brazil.
  • Negrete CL; 42522Sírio-Libanês Hospital, Brazil.
  • Eugênio E; 67754AMO Clinic, Brazil.
  • Moraes EL; 37908National Cancer Institute of Brazil, Brazil.
  • Livinalli A; CF Onco, Brazil.
J Oncol Pharm Pract ; 28(8): 1737-1748, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1463166
ABSTRACT

INTRODUCTION:

Cancer patients with Covid-19 are exposed to treatment combinations that can potentially result in interactions that adversely affect patient outcomes. This study aimed to identify potential drug-drug interactions between antineoplastic agents and medicines used to treat Covid-19.

METHODS:

We conducted a search for potential interactions between 201 antineoplastic agents and 26 medicines used to treat Covid-19 on the Lexicomp® and Micromedex® databases. The following data were extracted interaction severity ("major" and "contraindicated") and interaction effects (pharmacokinetic and pharmacodynamic). We also sought to identify the therapeutic indication of the antineoplastic drugs involved in the potential drug-drug interactions.

RESULTS:

A total of 388 "major" or "contraindicated" drug-drug interactions were detected. Eight drugs or combinations (baricitinib, lopinavir/ritonavir, atazanavir, darunavir, azithromycin, chloroquine, hydroxychloroquine, and sirolimus) accounted for 91.5% of these interactions. The class of antineoplastic agents with the greatest potential for interaction was tyrosine kinase inhibitors (accounting for 46.4% of all interactions). The findings show that atazanavir, baricitinib, and lopinavir/ritonavir can affect the treatment of all common types of cancer. The most common pharmacokinetic effect of the potential drug-drug interactions was increased plasma concentration of the antineoplastic medicine (39.4%).

CONCLUSIONS:

Covid-19 is a recent disease and pharmacological interventions are undergoing constant modification. This study identified a considerable number of potential drug-drug interactions. In view of the vulnerability of patients with cancer, it is vital that health professionals carefully assess the risks and benefits of drug combinations.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / COVID-19 Drug Treatment / Antineoplastic Agents Type of study: Prognostic study Limits: Humans Language: English Journal: J Oncol Pharm Pract Journal subject: Pharmacy Year: 2022 Document Type: Article Affiliation country: 10781552211040494

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / COVID-19 Drug Treatment / Antineoplastic Agents Type of study: Prognostic study Limits: Humans Language: English Journal: J Oncol Pharm Pract Journal subject: Pharmacy Year: 2022 Document Type: Article Affiliation country: 10781552211040494